Why the study?
Does an optimized protocol of heparin before transseptal puncture and intravenous aspirin reduce cerebral events during laserballoon ablation in patients with atrial fibrillation?
Does an optimized protocol of heparin before transseptal puncture and intravenous aspirin reduce cerebral events during laserballoon ablation in patients with atrial fibrillation?
An optimized protocol of heparin before transseptal puncture combined with intravenous aspirin significantly reduces the incidence of cerebral events during laserballoon ablation for atrial fibrillation.
Answers are grounded in this paper and cite their sources.
May support optimized heparin-aspirin protocols to lower cerebral events; hypothesis-generating pending randomized confirmation.
INTRODUCTION: Cerebral events (CEs), including silent (SCEs), are a known complication of left atrial catheter ablation (LACA) in patients with atrial fibrillation. The aim of this prospective registry was to gain more information about CEs during laserballoon LACA and to reduce the risk of their occurrence. METHODS AND Cerebral MRI (1.5 Tesla) was performed to detect CEs. ASPItest identified aspirin-resistant patients (ARPs). All bleeding complications were recorded. Due to an initial high CE rate, we evolved our clinical procedure step-by-step arriving at an optimized protocol: -Group 1: heparin after single transseptal puncture (TP), activated clotting time (ACT) > 300 seconds (CE: 64.3%). -Group 2: heparin after double TP, ACT > 300 seconds; 2a without (CE: 45.5%, RRR: -29.2%) and 2b with additional intravenous aspirin (CE: 36.4%, RRR: -43.4%; excluding ARP: 30%, RRR: -53.3%). -Group 3: heparin before double TP, ACT > 350 seconds; 3a without (CE: 54.5%, RRR: -15.2%) and 3b with aspirin (CE: 18.5%, RRR: -71.2%; excluding ARP: 8.7%, RRR: -86.5%). Larger LA diameter > 44 mm (OR: 1.149, P = 0.005) and no aspirin use (OR: 4.308, P = 0.008) were CE risk factors in multivariate logistic regression. In those patients receiving aspirin, aspirin resistance (OR: 22.4, P = 0.011) was an exceptionally strong risk factor. CONCLUSION: These data support the use of intravenous aspirin including monitoring of aspirin resistance in addition to ACT-guided heparin. An optimized protocol of heparin before TP, double TP, and intravenous aspirin in non-ARP resulted in a significantly lowered CE incidence and severity.
No takes yet. Share an insight, caveat, or question.
Eichenlaub et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: